Skip to content

Released May 3, 2024, before the open

10-Q filed May 3, 2024, 33 days after period end · 0001785530-24-000020

Q1 2024 · 10-Q
Revenue—
Net Income-$16.19MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.39N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$17,162,000N/M
Operating Cash Flow-$15,297,000N/M
Free Cash Flowderived-$15,408,000N/M

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Net Income-$16.19M-$11.98M-$15.34M-$7.44M
EPS Diluted-$0.39-$0.34-$0.56-$83.36

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR